Latest Articles

Publication Date
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair.

Endometriosis is a chronic, hormone-dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, …

Published: Feb. 18, 2026, midnight
Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... - Medical Dialogues

Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... Medical Dialogues

Published: Feb. 17, 2026, 3:15 p.m.
Study Finds GLP-1 Medications Combined with Progestin Therapy May Lower Endometrial Cancer Risk - geneonline.com

Study Finds GLP-1 Medications Combined with Progestin Therapy May Lower Endometrial Cancer Risk geneonline.com

Published: Feb. 16, 2026, 6:10 a.m.
Precision-based solutions for endometriosis: Integrating immunomics and drug repositioning strategies.

Endometriosis (EMs) is an estrogen-dependent, chronic inflammatory disorder characterized by immune microenvironment dysregulation, a critical factor in its pathogenesis. Despite existing therapies, limitations persist, highlighting the urgent need for innovative …

Published: Feb. 16, 2026, midnight
Differences in response to dienogest therapy among different phenotypes of endometriosis: A single-center retrospective cohort analysis.

This study aims to investigate the differences in response to dienogest (DNG) therapy among patients with 3 different phenotypes of endometriosis: ovarian endometrioma (OMA), superficial peritoneal endometriosis (SUP), and deep …

Published: Feb. 15, 2026, midnight
Associations of baseline characteristics, patient-reported outcomes, and satisfaction with pain therapy with the patient's global impression of change: a prospective cohort study.

Patient-reported outcome measures (PROMs) are key elements of assessing the efficacy of perioperative pain management. Here, we aimed to capture the association of 10 individually reported aspects of patient's specific …

Published: Feb. 13, 2026, midnight
2-Deoxyglucose dendrimer-enabled niclosamide delivery to FRβ-expressing macrophages alleviates endometriosis progression and associated hyperalgesia.

Endometriosis is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, non-hormonal therapies is urgently needed. We …

Published: Feb. 12, 2026, midnight
Impact of hormonal treatments for endometriosis on the reproductive microbiome: a systematic review.

The reproductive microbiome plays a key role in disease progression and fertility in women with endometriosis. Vaginal and endometrial dysbiosis has been increasingly linked to inflammation, impaired reproductive outcomes, and …

Published: Feb. 12, 2026, midnight
Diagnosis and Therapy of Endometriosis. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/045, April 2025).

Objective The objective of this revised official guideline, published by the German Society for Gynecology and Obstetrics (DGGG) and coordinated in the joint guidelines program of the DGGG, the Austrian …

Published: Feb. 11, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!